Nori Ebersole
Director/Board Member bij SIENTRA, INC.
Vermogen: 2 980 $ op 31-03-2024
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| James Robinson | M | 54 |
Urovant Sciences, Inc.
 Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The private company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 5 jaar |
| James Hindman | M | 63 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The private company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 36 jaar |
| Sef P. Kurstjens | M | 60 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The private company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 10 jaar |
| Caroline F. van Hove | F | 43 | 21 jaar | |
| Philippe Schaison | M | 62 | 11 jaar | |
| Cornelia Haag-Molkenteller | M | 66 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The private company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 17 jaar |
| Myrtle Potter | F | 65 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The private company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 6 jaar |
| Shigeyuki Nishinaka | M | 59 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The private company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 5 jaar |
| Pierre Legault | M | 63 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The private company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 6 jaar |
| Timothy Kirk Andrews | M | 45 | 10 jaar | |
| Ronald Menezes | M | 61 | 4 jaar | |
| Christine Ocampo | F | 51 | - | |
| Oliver Bennett | M | 47 | 9 jaar | |
| Irina Erenburg | M | 54 | 3 jaar | |
| Lisa Metzner | F | 55 | 10 jaar | |
| Rita Karachun | F | 63 | 1 jaar | |
| Ryan Kubota | M | - | - | |
| Mary Fisher | F | 62 | 5 jaar | |
| Denise Dajles | F | - | 3 jaar | |
| Alexander Casdin | M | 56 | 1 jaar | |
| Andrew Schmidt | M | 62 | 3 jaar | |
| Yuichiro Haruyama | M | - |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The private company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 3 jaar |
| Matt Hostetler | M | - | 2 jaar | |
| Allison Luo | M | 50 | 6 jaar | |
| Kenton Stewart | M | - | 4 jaar | |
| Christropher Doughty | M | - | 3 jaar | |
| Vika Brough | F | - | - | |
| John Lenell | M | - |
Big Brothers Big Sisters of Orange County
| - |
| Walt Johnston | M | - | 4 jaar | |
| Olivier Laurent | M | 52 | 4 jaar | |
| Jon Filderman | M | - | 1 jaar | |
| Ajay Bansal | M | 62 | 5 jaar | |
| Brian Stevens | M | 51 |
Big Brothers Big Sisters of Orange County
| 12 jaar |
| Jim Hindman | M | - |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The private company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 4 jaar |
| Patrick Maciariello | M | - |
Big Brothers Big Sisters of Orange County
| - |
| Vincent E. Mudd | M | - |
Big Brothers Big Sisters of Orange County
| - |
| Timothy Ryan | M | - |
Big Brothers Big Sisters of Orange County
| - |
| Jeffrey Jones | M | - | 5 jaar | |
| Brian R. Schaefgen | M | 53 |
Big Brothers Big Sisters of Orange County
| - |
| Aaron Rosenberg | M | - | 1 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Douglas Ingram | M | 61 | 19 jaar | |
| Keith Katkin | M | 52 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The private company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 3 jaar |
| Ambrose Bailey | M | 60 | 6 jaar | |
| David Hovland | M | - | 15 jaar | |
| Brenton Saunders | M | 56 | 6 jaar | |
| Paul Bisaro | M | 63 | 5 jaar | |
| Peter John McDonnell | M | 66 | 7 jaar | |
| Scott Giacobello | M | 54 | 7 jaar | |
| Michael R. Gallagher | M | 77 | 2 jaar | |
| Jeffrey Edwards | M | 64 | 22 jaar | |
| Mark Mckenna | M | 48 | 4 jaar | |
| Nicholas Simon | M | 67 | 14 jaar | |
| Maria Hilado | F | 59 | 4 jaar | |
| David Pyott | M | 70 | 17 jaar | |
| Bryan E. Smith | M | 45 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The private company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 10 jaar |
| Sanjiv Patel | M | 50 | 11 jaar | |
| David Adam Buchen | M | 59 | 1 jaar | |
| Vivid Sehgal | M | 56 | 8 jaar | |
| Keith Sullivan | M | 66 | 6 jaar | |
| Herb Boyer | M | 87 | 19 jaar | |
| C. Nicholson | M | 68 | 6 jaar | |
| Matthew Joseph Maletta | M | 52 | - | |
| Deborah Bettencourt | F | - | 15 jaar | |
| Nesli Basgoz | M | 66 | 6 jaar | |
| William Humphries | M | 57 | 8 jaar | |
| Les Kaplan | M | 73 | 21 jaar | |
| Helen Adams | F | 65 | 2 jaar | |
| Michael McFadden | M | 57 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The private company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 1 jaar |
| Charles McDermott | M | 51 | 8 jaar | |
| Noël Kurdi | F | - | 2 jaar | |
| Jonathon Kellerman | M | - | 6 jaar | |
| Keith Marshall | M | 56 | 3 jaar | |
| Roger J. Lias | M | 63 | 6 jaar | |
| Martin Hendrix | M | 56 | 3 jaar | |
| Judith Swain | M | 75 | 2 jaar | |
| Hafrun Fridriksdottir | M | 62 | 14 jaar | |
| John Kelly | M | 57 | 6 jaar | |
| Eric Brandt | M | 62 | 6 jaar | |
| Leonard Schaeffer | M | 78 | 18 jaar | |
| Andrew L. Turner | M | 77 | 2 jaar | |
| Christopher Coughlin | M | 71 | 6 jaar | |
| James H. Bloem | M | 73 | 5 jaar | |
| John A. King | M | 74 | 2 jaar | |
| Christopher Bodine | M | 68 | 11 jaar | |
| Robert Todd Joyce | M | 66 | 1 jaar | |
| Deborah Dunsire | M | 61 | 9 jaar | |
| Patrick O’Sullivan | M | 82 | 5 jaar | |
| George Frederick Wilkinson | M | 68 | 1 jaar | |
| Sigurdur Olafsson | M | 55 | 4 jaar | |
| Louis Lavigne | M | 75 | 10 jaar | |
| Catherine Klema | F | 65 | 15 jaar | |
| Fred G. Weiss | M | 82 | 18 jaar | |
| Kevin O'Boyle | M | 68 | 9 jaar | |
| Tamar Howson | F | 75 | 9 jaar | |
| Joseph Papa | M | 68 | 3 jaar | |
| Valerie J. Miller | F | 60 | 5 jaar | |
| Louis T. Rosso | M | - | 16 jaar | |
| Mary Szela | F | 61 | 2 jaar | |
| Jirí Michal | M | 71 | 2 jaar | |
| David Berk | M | 45 | 6 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigde Staten | 71 | 71.00% |
| Ierland | 33 | 33.00% |
| Verenigd Koninkrijk | 16 | 16.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Nori Ebersole
- Persoonlijk netwerk
